Bosutinib, sold under the brand name Bosulif, is a small molecule BCR-ABL and src tyrosine kinase inhibitor used for the treatment of chronic myelogenous...
10 KB (633 words) - 12:29, 5 August 2024
Bosutinib's activity was first described in 2001 and it was disclosed as an Abl kinase inhibitor in 2003. At first it was believed that bosutinib was...
56 KB (6,475 words) - 07:21, 26 August 2024
approved in South Korea for people resistant to or intolerant of imatinib. Bosutinib received US FDA and EU European Medicines Agency approval on 4 September...
34 KB (3,877 words) - 01:25, 22 July 2024
(ALK) Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase Baricitinib Fedratinib...
12 KB (794 words) - 03:30, 2 September 2024
Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib (Scemblix) Bortezomib (Velcade)...
20 KB (2,234 words) - 01:21, 22 July 2024
available inhibitors to treat CML are imatinib, dasatinib, nilotinib, bosutinib and ponatinib. Gastrointestinal stromal tumors (GIST) are known to withstand...
43 KB (5,251 words) - 10:44, 24 June 2024
(ALK) Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase Baricitinib Fedratinib...
12 KB (758 words) - 23:46, 14 March 2024
Pharmaceuticals) Borofax bortezomib (USAN) Bosatria (GlaxoSmithKline) bosentan (INN) bosutinib (USAN, INN) botiacrine (INN) Botox (Allergan) Boudreaux's Butt Paste (Blairex...
8 KB (401 words) - 04:48, 5 August 2024
injectables such as the EpiPen. On September 4, 2012, the FDA approved bosutinib (Bosulif) for chronic myelogenous leukemia (CML), a rare type of leukemia...
167 KB (14,521 words) - 00:40, 7 September 2024
for "Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs" at ClinicalTrials.gov Portal:...
17 KB (1,263 words) - 09:31, 30 July 2024